Covered on cash flow, flagged on reported earnings. A 2.34% yield whose reported payout — 267% of trailing earnings — looks uncovered until the basis is stated: the trailing figure is distorted by large one-time acquisition charges, and on a cash-flow basis the payout runs about 30%. $0.85 a quarter, raised from $0.81 in late 2025 with 15 years of increases behind it, is covered by cash — but the reported number is the flag, and it stays on the card until earnings normalize.
Key risk: Keytruda patent exposure plus acquisition charges — the flagship oncology franchise faces loss of exclusivity later this decade, and the deal-driven charges that distort reported earnings also show how much pipeline renewal is costing.
Changes if: Cash-flow payout rises past about 60%, or reported earnings stay depressed long enough that the 267% figure stops looking like a one-time distortion. Either would move this from flagged to failing.
- !Payout-coverage check: 267% of reported trailing earnings — distorted by one-time acquisition charges, including a $2.31-per-share charge in Q2 2026; on a cash-flow basis the payout runs about 30%, which is the basis this card's coverage rests on.
- ✓Yield check: 2.34% indicated — $0.85/qtr × 4 at the $145.27 close on Oct. 23, 2026. Real, earned yield for a single stock.
- ✓Dividend growth check: 15 years of increases; the latest step, from $0.81 to $0.85, was paid Oct. 7, 2026.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.